By: Lalani H.B. No. 386
 
 
 
A BILL TO BE ENTITLED
 
AN ACT
  relating to health benefit plan coverage of treatments for
  pediatric neuroinflammatory disorder.
         BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
         SECTION 1.  Chapter 1367, Insurance Code, is amended by
  adding Subchapter H to read as follows:
  SUBCHAPTER H. PEDIATRIC NEUROINFLAMMATORY DISORDERS
         Sec. 1367.351.  DEFINITIONS. In this subchapter:
               (1)  "Off-label use" means the use of a prescription
  drug or therapy approved for use by the United States Food and Drug
  Administration in a manner other than the approved use.
               (2)  "Pediatric neuroinflammatory disorder" means an
  immune-mediated inflammatory condition affecting the central
  nervous system in an individual younger than 18 years of age,
  including but not limited to autoimmune encephalitis,
  post-infectious encephalitis, acute disseminated
  encephalomyelitis (ADEM), optic neuritis, transverse myelitis,
  neuromyelitis optica spectrum disorder (NMOSD), pediatric
  acute-onset neuropsychiatric syndrome (PANS), pediatric autoimmune
  neuropsychiatric disorders associated with streptococcal
  infections (PANDAS), and other clinically recognized neuroimmune
  or neuroinflammatory disorders diagnosed by a physician using
  accepted clinical criteria, diagnostic testing, and clinical
  judgment.
         Sec. 1367.352.  APPLICABILITY OF SUBCHAPTER.  (a)  This
  subchapter applies only to a health benefit plan that provides
  benefits for medical, surgical, or prescription drug expenses
  incurred as a result of a health condition, accident, or sickness,
  including an individual, group, blanket, or franchise insurance
  policy or insurance agreement, a group hospital service contract,
  or an individual or group evidence of coverage or similar coverage
  document that is issued by:
               (1)  an insurance company;
               (2)  a group hospital service corporation operating
  under Chapter 842;
               (3)  a health maintenance organization operating under
  Chapter 843;
               (4)  an approved nonprofit health corporation that
  holds a certificate of authority under Chapter 844;
               (5)  a multiple employer welfare arrangement that holds
  a certificate of authority under Chapter 846;
               (6)  a stipulated premium company operating under
  Chapter 884;
               (7)  a fraternal benefit society operating under
  Chapter 885;
               (8)  a Lloyd's plan operating under Chapter 941; or
               (9)  an exchange operating under Chapter 942.
         (b)  Notwithstanding any other law, this subchapter applies
  to:
               (1)  a basic coverage plan under Chapter 1551;
               (2)  a basic plan under Chapter 1575; and
               (3)  a primary care coverage plan under Chapter 1579.
         Sec. 1367.353.  COVERAGE REQUIRED.  (a)  A health benefit
  plan must provide coverage for the treatment of pediatric
  neuroinflammatory disorder if:
               (1)  that condition was diagnosed by a physician with
  appropriate specialty training, including neurology, pediatric
  neurology, pediatric immunology, pediatric rheumatology, and an
  equivalent specialty, based on accepted clinical criteria,
  diagnostic testing, and the physician's clinical judgment;
               (2)  the treatment is prescribed by the enrollee's
  treating physician as medically necessary for an individual
  diagnosed with that condition; and
               (3)  the enrollee's treating physician documents, in
  the enrollee's medical record, the clinical rationale for the
  treatment and the basis for the diagnosis of that condition.
         (b)  The coverage required by this section must include
  coverage of:
               (1)  the following treatments:
                     (A)  immunomodulating therapies, including:
                           (i)  intravenous immunoglobulin therapy;
                           (ii)  rituximab;
                           (iii)  therapeutic plasma exchange;
                           (iv)  cyclophosphamide;
                           (v)  mycophenolate mofetil;
                           (vi)  azathioprine; and
                           (vii)  other disease-modifying therapies
  used to treat pediatric neuroinflammatory disorder under accepted
  clinical practices;
                     (B)  antibiotics; and
                     (C)  behavioral therapy;
               (2)  costs related to inpatient or outpatient
  administration of a treatment described by Subdivision (1),
  including infusion services; and
               (3)  any other costs associated with administering a
  treatment described by Subdivision (1), including clinical
  monitoring, laboratory testing, imaging, and other ancillary
  services.
         (c)  In determining whether a treatment is medically
  necessary under this section, a health benefit plan issuer shall
  give substantial deference to the clinical judgment of the
  enrollee's treating physician who has appropriate experience in
  diagnosing or treating pediatric neuroimmune or neuroinflammatory
  disorders, taking into consideration the enrollee's clinical
  presentation, diagnostic findings, treatment history, and response
  to previous treatment.
         Sec. 1367.354.  APPROVAL OF TREATMENT. A health benefit
  plan issuer may not deny or delay approval of a treatment for which
  coverage is required under Section 1367.353 on the sole basis that:
               (1)  the treatment is prescribed for an off-label use
  or is classified by the health benefit plan issuer as experimental
  or investigational, if the treatment is medically necessary and
  supported by peer-reviewed medical literature, recognized clinical
  practice guidelines, or other generally accepted medical evidence
  applicable to the enrollee's condition;
               (2)  the enrollee has previously received the same
  treatment for pediatric neuroinflammatory disorder or another
  diagnosis; or
               (3)  the enrollee's diagnosis is listed under a
  diagnostic code or label other than pediatric neuroinflammatory
  disorder.
         Sec. 1367.355.  LIMIT ON COST-SHARING REQUIREMENT. A health
  benefit plan issuer may not impose a cost-sharing requirement,
  including a copayment, coinsurance cost, or deductible for a
  treatment required to be covered under Section 1367.353 that is
  greater than the cost-sharing requirement applied to other covered
  health care services within the same benefit tier under the
  enrollee's health benefit plan.
         Sec. 1367.356.  PROHIBITION ON MULTIPLE PREAUTHORIZATIONS.
  For purposes of this section, a subsequent prescription, treatment
  order, infusion, or administration of the same treatment during the
  applicable 12-month period does not constitute a new treatment
  requiring additional preauthorization solely because the treatment
  is prescribed or administered in separate doses or courses,
  provided the treatment remains medically necessary for the covered
  condition under Section 1367.353.
         Sec. 1367.357.  REPORTING. (a) The department shall:
               (1)  collect data on any denial or appeal of a denial of
  a treatment required to be covered under Section 1367.353; and
               (2)  annually submit to the legislature a written
  report summarizing the data collected under Subdivision (1).
         (b)  The department may require a health benefit plan issuer
  to submit data to the department in the form and manner prescribed
  by the commissioner for purposes of complying with this subchapter.
         SECTION 2.  The changes in law made by this Act apply only to
  a health benefit plan that is delivered, issued for delivery, or
  renewed on or after January 1, 2028.
         SECTION 3.  This Act takes effect September 1, 2027.